❗Let's close the gap: We still need your help to raise $40,000 by April 1. Donate now

From This Collection

AstraZeneca vaccine is third to show promising data in unprecedented hurry-up race

Nov 23, 2020
The COVID-19 vaccine is being produced so quickly due to a combination of factors involving the research community, government, industry and the public.
A volunteer receives a COVID-19 vaccination at the Research Centers of America in Hollywood, Florida.
Chandan Khanna/AFP via Getty Images

Hard decisions loom in prioritizing who gets COVID-19 vaccine first

Nov 11, 2020
"There will be consequences, always, from these choices," says former WHO chair David Salisbury. "But we try to make them with the best interests of the most people at heart."
"The real big challenge for COVID vaccination is that we're talking not just about people at risk, but we're talking about everybody," says David Salisbury, former chair of the World Health Organization's Strategic Advisory Group of Experts on Immunization.
Chandan Khanna/AFP via Getty Images

Vaccine experts see hurdles in fighting efficacy, safety misinformation

Nov 10, 2020
As of now, confidence in a potential COVID-19 vaccine is lower than confidence in other vaccines, one specialist says.
Heidi Larson, director of Vaccine Confidence Project, says people are most concerned about the safety of a new COVID-19 vaccine.
David Dee Delgado/Getty Images

Researchers work to diversify clinical trials of COVID-19 vaccine

Nov 10, 2020
Researchers say they must overcome deep mistrust of medical research in the Black, Latinx and Native American communities in recruiting volunteers for vaccine testing.
Joe Raedle/Getty Images

Why Pfizer says it pushed for transparency and diversity in vaccine development process

Nov 9, 2020
To build public trust, Pfizer shared details of their trials: who was tested, the race and ethnicity of participants, how they were monitored, how to measure success and funding sources.
A person walks by Pfizer headquarters on Nov. 9, 2020, in New York City. Transparency is key for a vaccine-skeptical public.
David Dee Delgado/Getty Images

No, there aren’t millions of glass vials waiting for a coronavirus vaccine yet

Oct 23, 2020
The manufacturing can't happen until suppliers know exactly which vaccine candidates they're working with.
The cash inflows have increased massively for mRNA technology. Where is that money coming from, and what could it mean for potential innovations?
Vincenzo Pinto/Getty Images

DHL exec says "big challenge" for vaccine distribution is "joint effort" between governments, producers

Oct 14, 2020
Katja Busch says efficient vaccine distribution is most dependent on coordinated efforts between the involved parties.
Mohammed Mahjoub/AFP via Getty Images

For public good, not for profit.

States are scrambling to build vaccine distribution infrastructure

Oct 8, 2020
Health departments will need trained personnel and equipment like syringes and vials. And states want special funding.
A volunteer receives a COVID-19 vaccination in a trial at the Research Centers of America in Hollywood, Florida, in August.
Chandan Khanna/AFP via Getty Images

Are cargo companies ready to distribute a COVID vaccine?

Oct 7, 2020
Julian Sutch, head of Emirates SkyCargo's pharmaceutical division, believes carriers like his are up to the task of global vaccine distribution, but acknowledge there are plenty of challenges to overcome.
That task could prove to be a huge issue for private cargo companies, especially air cargo transporters, if a potential vaccine requires specific storage conditions like extreme cold.
Stan Honda/AFP via Getty Images

World Bank proposes a $12 billion fund for COVID vaccine dispersal to poor and developing countries

Oct 5, 2020
World Bank President David Malpass believes his institution will be well situated to both fund and assist in a global COVID vaccine distribution effort.
"Up to $12 billion is a signal to the pharmaceutical manufacturers that there's going to be a big demand, and that there's financing for it, and that the countries will be looking for a safe vaccine. And so it fills that void that would otherwise be there," says World Bank President David Malpass.
Sajjad Hussain/AFP via Getty Images